{"transactions":[{"id":4615577,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-11T11:30:02.000Z","date":"2026-09-10","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":4.1,"value":410000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Purchase prices range from $4.03 to $4.11 per share, inclusive"}],"balance_after":1500000,"source":{"system":"sec-edgar","filing":"0001213900-26-098969","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1565832/000121390026098969/ownership.xml","form_type":"4"}},{"id":4615576,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-11T11:30:02.000Z","date":"2026-09-09","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":4.18,"value":418000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchase prices range from $4.15 to $4.22 per share, inclusive."}],"balance_after":1400000,"source":{"system":"sec-edgar","filing":"0001213900-26-098969","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1565832/000121390026098969/ownership.xml","form_type":"4"}},{"id":967123,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Appreciation Rights","published_at":"2025-12-16T14:30:49.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":1198000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026."}],"balance_after":1198000,"derivative":{"exercise_price":4.06,"exercise_date":"2026-03-12","expiration_date":"2035-12-12","underlying":"Common Stock","underlying_shares":1198000},"source":{"system":"sec-edgar","filing":"0001213900-25-121974","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025121974/ownership.xml","form_type":"4"}},{"id":967122,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-16T14:30:49.000Z","date":"2025-12-15","kind":"purchase","planned":false,"acquired":true,"shares":27500,"price":4.12,"value":113300.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchase prices range from $4.10 to $4.12 per share, inclusive."}],"balance_after":1300000,"source":{"system":"sec-edgar","filing":"0001213900-25-121974","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025121974/ownership.xml","form_type":"4"}},{"id":1005606,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-11-06T12:30:04.000Z","date":"2025-11-05","kind":"purchase","planned":false,"acquired":true,"shares":272500,"price":2.2,"value":599500.0,"ownership":{"direct":true},"balance_after":1272500,"source":{"system":"sec-edgar","filing":"0001213900-25-106837","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025106837/ownership.xml","form_type":"4"}},{"id":1053449,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-08-28T20:56:35.000Z","date":"2025-08-28","kind":"purchase","planned":false,"acquired":true,"shares":55976,"price":0.74,"value":41422.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Purchase prices range from $0.68 to $0.79 per share, inclusive."}],"balance_after":1000000,"source":{"system":"sec-edgar","filing":"0001213900-25-081837","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025081837/ownership.xml","form_type":"4"}},{"id":1053448,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-08-28T20:56:35.000Z","date":"2025-08-27","kind":"purchase","planned":false,"acquired":true,"shares":129455,"price":0.67,"value":86734.85,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Purchase prices range from $0.65 to $0.69 per share, inclusive."}],"balance_after":944024,"source":{"system":"sec-edgar","filing":"0001213900-25-081837","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025081837/ownership.xml","form_type":"4"}},{"id":1053447,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-08-28T20:56:35.000Z","date":"2025-08-26","kind":"purchase","planned":false,"acquired":true,"shares":80545,"price":0.62,"value":49937.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchase prices range from $0.61 to $0.65 per share, inclusive."}],"balance_after":814569,"source":{"system":"sec-edgar","filing":"0001213900-25-081837","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025081837/ownership.xml","form_type":"4"}},{"id":1098993,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-06-30T23:28:46.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in 16 equal quarterly installments commencing on September 26, 2025."}],"balance_after":800000,"derivative":{"exercise_price":0.67,"exercise_date":"2025-09-26","expiration_date":"2035-06-26","underlying":"Common Stock","underlying_shares":800000},"source":{"system":"sec-edgar","filing":"0001213900-25-059868","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025059868/ownership.xml","form_type":"4"}},{"id":1140065,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-05-20T22:01:43.000Z","date":"2025-05-20","kind":"purchase","planned":false,"acquired":true,"shares":147686,"price":0.5569,"value":82246.3334,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Purchase prices range from $0.53 to $0.59 per share, inclusive."}],"balance_after":734024,"source":{"system":"sec-edgar","filing":"0001213900-25-046085","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025046085/ownership.xml","form_type":"4"}},{"id":1140064,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-05-20T22:01:43.000Z","date":"2025-05-19","kind":"purchase","planned":false,"acquired":true,"shares":30000,"price":0.4998,"value":14994.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Purchase prices range from $0.4998 to $0.50 per share, inclusive."}],"balance_after":586338,"source":{"system":"sec-edgar","filing":"0001213900-25-046085","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025046085/ownership.xml","form_type":"4"}},{"id":1140063,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-05-20T22:01:43.000Z","date":"2025-05-16","kind":"purchase","planned":false,"acquired":true,"shares":172314,"price":0.4496,"value":77472.3744,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchase prices range from $0.4485 to $0.4564 per share, inclusive."}],"balance_after":556338,"source":{"system":"sec-edgar","filing":"0001213900-25-046085","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025046085/ownership.xml","form_type":"4"}},{"id":1409480,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-11T21:47:15.000Z","date":"2024-09-11","kind":"purchase","planned":false,"acquired":true,"shares":51407,"price":2.99,"value":153706.93,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Purchase prices range from $2.84 to $3.05 per share, inclusive."}],"balance_after":384024,"source":{"system":"sec-edgar","filing":"0001213900-24-077795","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024077795/ownership.xml","form_type":"4"}},{"id":1409479,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-11T21:47:15.000Z","date":"2024-09-10","kind":"purchase","planned":false,"acquired":true,"shares":33014,"price":2.75,"value":90788.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Purchase prices range from $2.73 to $2.80 per share, inclusive."}],"balance_after":332617,"source":{"system":"sec-edgar","filing":"0001213900-24-077795","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024077795/ownership.xml","form_type":"4"}},{"id":1409478,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-11T21:47:15.000Z","date":"2024-09-09","kind":"purchase","planned":false,"acquired":true,"shares":55579,"price":2.71,"value":150619.09,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchase prices range from $2.51 to $2.85 per share, inclusive."}],"balance_after":299603,"source":{"system":"sec-edgar","filing":"0001213900-24-077795","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024077795/ownership.xml","form_type":"4"}},{"id":1498839,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-30T01:25:08.000Z","date":"2024-05-24","kind":"other","planned":false,"acquired":false,"shares":122358,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On May 24, 2024, the Reporting Person voluntarily forfeited to the Issuer a portion of the December Award equal to the Additional Award Shares so that those shares can be allocated to the holders of Similar Awards who are not executive officers or directors of the Issuer."}],"balance_after":183881,"derivative":{"exercise_price":2.48,"exercise_date":"2024-03-15","expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":122358},"source":{"system":"sec-edgar","filing":"0001213900-24-047639","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024047639/ownership.xml","form_type":"4"}},{"id":1498838,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-30T01:25:08.000Z","date":"2024-05-24","kind":"grant","planned":false,"acquired":true,"shares":122358,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 24, 2024, under the terms of the option award granted to the Reporting Person on December 15, 2023 (the \"December Award\"), the Reporting Person became entitled to receive options for up to 122,358 additional shares of the Issuer's Common Stock on the same terms as the December Award (the \"Additional Award Shares\") out of shares that had become available under the terms of the Issuer's 2021 Equity Incentive Plan, as amended (the \"Plan\"), since December 15, 2023, as a result of expirations, cancelations, forfeitures and terminations of other outstanding awards under the Plan and/or tenders or withholding of shares."}],"balance_after":306239,"derivative":{"exercise_price":2.48,"exercise_date":"2024-03-15","expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":122358},"source":{"system":"sec-edgar","filing":"0001213900-24-047639","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024047639/ownership.xml","form_type":"4"}},{"id":1664883,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-31T23:29:27.000Z","date":"2024-01-31","kind":"purchase","planned":false,"acquired":true,"shares":27460,"price":3.9968,"value":109752.128,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Purchase prices range from $3.95 to $4.05 per share, inclusive."}],"balance_after":244024,"source":{"system":"sec-edgar","filing":"0001213900-24-008560","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024008560/ownership.xml","form_type":"4"}},{"id":1664882,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-31T23:29:27.000Z","date":"2024-01-30","kind":"purchase","planned":false,"acquired":true,"shares":40999,"price":3.9013,"value":159949.3987,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Purchase prices range from $3.88 to $3.97 per share, inclusive."}],"balance_after":216564,"source":{"system":"sec-edgar","filing":"0001213900-24-008560","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024008560/ownership.xml","form_type":"4"}},{"id":1664881,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-31T23:29:27.000Z","date":"2024-01-29","kind":"purchase","planned":false,"acquired":true,"shares":31541,"price":3.7106,"value":117036.0346,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchase prices range from $3.69 to $3.75 per share, inclusive."}],"balance_after":175565,"source":{"system":"sec-edgar","filing":"0001213900-24-008560","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024008560/ownership.xml","form_type":"4"}},{"id":1704384,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-12-19T22:28:56.000Z","date":"2023-12-15","kind":"grant","planned":false,"acquired":true,"shares":183881,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in 16 equal quarterly installments commencing on March 15, 2024."}],"balance_after":183881,"derivative":{"exercise_price":2.48,"exercise_date":"2024-03-15","expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":183881},"source":{"system":"sec-edgar","filing":"0001213900-23-097032","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023097032/ownership.xml","form_type":"4"}},{"id":1874291,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-05-30T21:10:46.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":527211,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the Board of Directors of the Company on December 16, 2022, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan, as amended (the \"Plan\"), increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2023, at the 2023 Annual Meeting of the Company's shareholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"80,728 of the options immediately vested; 770,000 options vest in 16 equal quarterly installments commencing on March 16, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"80,728 of the options immediately vested; 770,000 options vest in 16 equal quarterly installments commencing on March 16, 2023."}],"balance_after":850728,"derivative":{"exercise_price":3.37,"exercise_date":"2022-12-16","expiration_date":"2032-12-16","underlying":"Common Stock","underlying_shares":527211},"source":{"system":"sec-edgar","filing":"0001213900-23-044093","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023044093/ownership.xml","form_type":"4"}},{"id":2030241,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-06T22:39:14.000Z","date":"2022-09-28","kind":"gift","acquired":false,"shares":87500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The options were granted on January 7, 2021. 25% of the options vested one year from the grant date, and thereafter in equal quarterly increments of 6.25% over the following three years."}],"balance_after":162500,"derivative":{"exercise_price":33.43,"expiration_date":"2031-01-07","underlying":"Common Stock","underlying_shares":87500},"source":{"system":"sec-edgar","filing":"0001213900-23-008514","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023008514/ownership.xml","form_type":"5/A","original_submission_date":"2023-02-02"}},{"id":2030240,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-06T22:39:14.000Z","date":"2022-09-28","kind":"gift","acquired":false,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The options were granted on January 7, 2021. 6.25% of the options vest each quarter from the date of grant."}],"balance_after":162500,"derivative":{"exercise_price":33.43,"expiration_date":"2031-01-07","underlying":"Common Stock","underlying_shares":62500},"source":{"system":"sec-edgar","filing":"0001213900-23-008514","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023008514/ownership.xml","form_type":"5/A","original_submission_date":"2023-02-02"}},{"id":2030239,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-06T22:39:14.000Z","date":"2021-07-08","kind":"gift","acquired":false,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The options were granted on January 7, 2021. 6.25% of the options vest each quarter from the date of grant."}],"balance_after":225000,"derivative":{"exercise_price":33.43,"expiration_date":"2031-01-07","underlying":"Common Stock","underlying_shares":31250},"source":{"system":"sec-edgar","filing":"0001213900-23-008514","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023008514/ownership.xml","form_type":"5/A","original_submission_date":"2023-02-02"}},{"id":2030238,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-06T22:39:14.000Z","date":"2021-07-08","kind":"gift","acquired":false,"shares":131250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options were granted on December 19, 2019. 6.25% of the options vest each quarter from the date of grant."}],"balance_after":218750,"derivative":{"exercise_price":43.47,"expiration_date":"2029-12-19","underlying":"Common Stock","underlying_shares":131250},"source":{"system":"sec-edgar","filing":"0001213900-23-008514","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023008514/ownership.xml","form_type":"5/A","original_submission_date":"2023-02-02"}},{"id":2030237,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-06T22:39:14.000Z","date":"2021-07-08","kind":"gift","acquired":false,"shares":8231,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options were granted on February 15, 2015. 6.25% of the options vested each quarter from the date of grant."}],"balance_after":3019,"derivative":{"exercise_price":54,"expiration_date":"2025-02-23","underlying":"Common Stock","underlying_shares":8231},"source":{"system":"sec-edgar","filing":"0001213900-23-008514","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023008514/ownership.xml","form_type":"5/A","original_submission_date":"2023-02-02"}},{"id":2030236,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-06T22:39:14.000Z","date":"2021-07-08","kind":"gift","acquired":false,"shares":27123,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options were granted on September 30, 2013. 25% of the options vested upon the date of grant and the remaining 75% of the options vested in equal quarterly increments over the next four (4) years, so that the last set of options vested in September 2017."}],"balance_after":6165,"derivative":{"exercise_price":16,"expiration_date":"2023-09-30","underlying":"Common Stock","underlying_shares":27123},"source":{"system":"sec-edgar","filing":"0001213900-23-008514","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023008514/ownership.xml","form_type":"5/A","original_submission_date":"2023-02-02"}},{"id":2030235,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-06T22:39:14.000Z","date":"2021-07-08","kind":"gift","acquired":false,"shares":4131,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options were granted on July 10, 2012. 25% of the options vested upon the grant date and the remaining 75% of the options vested in equal quarterly increments over the next four (4) years, so that the last set of options vested in July 2016."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2022-07-10","underlying":"Common Stock","underlying_shares":4131},"source":{"system":"sec-edgar","filing":"0001213900-23-008514","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023008514/ownership.xml","form_type":"5/A","original_submission_date":"2023-02-02"}},{"id":2035232,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T22:01:35.000Z","date":"2021-07-08","kind":"gift","acquired":false,"shares":87500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The options were granted on January 7, 2021. 25% of the options vested one year from the grant date, and thereafter in equal quarterly increments of 6.25% over the following three years."}],"balance_after":162500,"derivative":{"exercise_price":33.43,"expiration_date":"2031-01-07","underlying":"Common Stock","underlying_shares":87500},"source":{"system":"sec-edgar","filing":"0001213900-23-007440","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023007440/ownership.xml","form_type":"5"}},{"id":2035231,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T22:01:35.000Z","date":"2021-07-08","kind":"gift","acquired":false,"shares":93750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The options were granted on January 7, 2021. 6.25% of the options vest each quarter from the date of grant."}],"balance_after":162500,"derivative":{"exercise_price":33.43,"expiration_date":"2031-01-07","underlying":"Common Stock","underlying_shares":93750},"source":{"system":"sec-edgar","filing":"0001213900-23-007440","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023007440/ownership.xml","form_type":"5"}},{"id":2035230,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T22:01:35.000Z","date":"2021-07-08","kind":"gift","acquired":false,"shares":131250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options were granted on December 19, 2019. 6.25% of the options vest each quarter from the date of grant."}],"balance_after":218750,"derivative":{"exercise_price":43.47,"expiration_date":"2029-12-19","underlying":"Common Stock","underlying_shares":131250},"source":{"system":"sec-edgar","filing":"0001213900-23-007440","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023007440/ownership.xml","form_type":"5"}},{"id":2035229,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T22:01:35.000Z","date":"2021-07-08","kind":"gift","acquired":false,"shares":8231,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options were granted on February 15, 2015. 6.25% of the options vested each quarter from the date of grant."}],"balance_after":3019,"derivative":{"exercise_price":54,"expiration_date":"2025-02-23","underlying":"Common Stock","underlying_shares":8231},"source":{"system":"sec-edgar","filing":"0001213900-23-007440","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023007440/ownership.xml","form_type":"5"}},{"id":2035228,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T22:01:35.000Z","date":"2021-07-08","kind":"gift","acquired":false,"shares":27123,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options were granted on September 30, 2013. 25% of the options vested upon the date of grant and the remaining 75% of the options vested in equal quarterly increments over the next four (4) years, so that the last set of options vested in September 2017."}],"balance_after":6165,"derivative":{"exercise_price":16,"expiration_date":"2023-09-30","underlying":"Common Stock","underlying_shares":27123},"source":{"system":"sec-edgar","filing":"0001213900-23-007440","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023007440/ownership.xml","form_type":"5"}},{"id":2035227,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T22:01:35.000Z","date":"2021-07-08","kind":"gift","acquired":false,"shares":4131,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift of stock options to a family trust. An independent trustee is trustee of the trust."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options were granted on July 10, 2012. 25% of the options vested upon the grant date and the remaining 75% of the options vested in equal quarterly increments over the next four (4) years, so that the last set of options vested in July 2016."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2022-07-10","underlying":"Common Stock","underlying_shares":4131},"source":{"system":"sec-edgar","filing":"0001213900-23-007440","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023007440/ownership.xml","form_type":"5"}},{"id":2079464,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-12-21T00:31:43.000Z","date":"2022-12-16","kind":"other","acquired":false,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the termination of milestone-based stock options granted to the reporting person on May 25, 2022, that were eligible to vest based on achievement of certain corporate objectives by the Issuer. Upon grant, the target vesting amount was reported in Table II of Form 4. On December 16, 2022, the Board of Directors determined that such milestone objectives were not achieved by the Issuer and that all 300,000 options would be terminated."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the termination of milestone-based stock options granted to the reporting person on May 25, 2022, that were eligible to vest based on achievement of certain corporate objectives by the Issuer. Upon grant, the target vesting amount was reported in Table II of Form 4. On December 16, 2022, the Board of Directors determined that such milestone objectives were not achieved by the Issuer and that all 300,000 options would be terminated."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Not applicable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Original expiration date."}],"balance_after":0,"derivative":{"exercise_price":19.03,"expiration_date":"2031-12-17","underlying":"Common stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001213900-22-081520","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390022081520/ownership.xml","form_type":"4"}},{"id":2079462,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-12-20T22:34:33.000Z","date":"2022-12-16","kind":"grant","acquired":true,"shares":323517,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"80,728 of the shares are immediately vested; 242,789 shares vest in 16 equal quarterly installments commencing on March 16, 2023."}],"balance_after":323517,"derivative":{"exercise_price":3.37,"exercise_date":"2022-12-16","expiration_date":"2032-12-16","underlying":"Common Stock","underlying_shares":323517},"source":{"system":"sec-edgar","filing":"0001213900-22-081481","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390022081481/ownership.xml","form_type":"4"}},{"id":2089326,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-13T01:00:42.000Z","date":"2022-12-08","kind":"purchase","acquired":true,"shares":55250,"price":2.096,"value":115804.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchase prices range from $2.05 to $2.13 per share, inclusive."}],"balance_after":144024,"source":{"system":"sec-edgar","filing":"0001213900-22-079244","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390022079244/ownership.xml","form_type":"4"}},{"id":2213976,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-05T20:30:38.000Z","date":"2022-07-01","kind":"exercise","acquired":false,"shares":13755,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 reflects the exercise of stock options set to expire on July 10, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The options were granted on July 10, 2012 (the \"Grant Date\"). 25% of the options vested upon the Grant Date and the remaining 75% of the options vested in equal quarterly increments over the next four (4) years, so that the last set of options vested in July 2016."}],"balance_after":0,"derivative":{"exercise_price":16,"exercise_date":"2012-07-10","expiration_date":"2022-07-10","underlying":"Common Stock","underlying_shares":13755},"source":{"system":"sec-edgar","filing":"0001213900-22-037231","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390022037231/ownership.xml","form_type":"4"}},{"id":2213975,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-05T20:30:38.000Z","date":"2022-06-30","kind":"exercise","acquired":false,"shares":16012,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 reflects the exercise of stock options set to expire on July 10, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The options were granted on July 10, 2012 (the \"Grant Date\"). 25% of the options vested upon the Grant Date and the remaining 75% of the options vested in equal quarterly increments over the next four (4) years, so that the last set of options vested in July 2016."}],"balance_after":13755,"derivative":{"exercise_price":16,"exercise_date":"2012-07-10","expiration_date":"2022-07-10","underlying":"Common Stock","underlying_shares":16012},"source":{"system":"sec-edgar","filing":"0001213900-22-037231","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390022037231/ownership.xml","form_type":"4"}},{"id":2213974,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-07-05T20:30:38.000Z","date":"2022-07-01","kind":"sale","acquired":false,"shares":4068,"price":18.32,"value":74525.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Sales prices range from $18.26 to $18.44 per share, inclusive."}],"balance_after":88774,"source":{"system":"sec-edgar","filing":"0001213900-22-037231","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390022037231/ownership.xml","form_type":"4"}},{"id":2213973,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-07-05T20:30:38.000Z","date":"2022-07-01","kind":"sale","acquired":false,"shares":8848,"price":18.45,"value":163245.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Sales prices range from $18.45 to $18.47 per share, inclusive."}],"balance_after":92842,"source":{"system":"sec-edgar","filing":"0001213900-22-037231","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390022037231/ownership.xml","form_type":"4"}},{"id":2213972,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-07-05T20:30:38.000Z","date":"2022-07-01","kind":"sale","acquired":false,"shares":839,"price":18.48,"value":15504.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Sales prices range from $18.47 to $18.53 per share, inclusive."}],"balance_after":101690,"source":{"system":"sec-edgar","filing":"0001213900-22-037231","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390022037231/ownership.xml","form_type":"4"}},{"id":2213971,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-07-05T20:30:38.000Z","date":"2022-07-01","kind":"exercise","acquired":true,"shares":13755,"price":16,"value":220080.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 reflects the exercise of stock options set to expire on July 10, 2022."}],"balance_after":102529,"source":{"system":"sec-edgar","filing":"0001213900-22-037231","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390022037231/ownership.xml","form_type":"4"}},{"id":2213970,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-07-05T20:30:38.000Z","date":"2022-06-30","kind":"sale","acquired":false,"shares":10698,"price":19.01,"value":203368.98,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Sales prices range from $19.00 to $19.15 per share, inclusive."}],"balance_after":88774,"source":{"system":"sec-edgar","filing":"0001213900-22-037231","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390022037231/ownership.xml","form_type":"4"}},{"id":2213969,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-07-05T20:30:38.000Z","date":"2022-06-30","kind":"sale","acquired":false,"shares":5314,"price":19.37,"value":102932.18,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Sales prices range from $19.20 to $19.51 per share, inclusive."}],"balance_after":99472,"source":{"system":"sec-edgar","filing":"0001213900-22-037231","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390022037231/ownership.xml","form_type":"4"}},{"id":2213968,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-07-05T20:30:38.000Z","date":"2022-06-30","kind":"exercise","acquired":true,"shares":16012,"price":16,"value":256192.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 reflects the exercise of stock options set to expire on July 10, 2022."}],"balance_after":104786,"source":{"system":"sec-edgar","filing":"0001213900-22-037231","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390022037231/ownership.xml","form_type":"4"}},{"id":2254907,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T22:45:02.000Z","date":"2022-05-25","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the \"Plan\") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"50% of the option shall vest when the Board of Directors or Compensation Committee has determined that 301, 302 and 303 Trials of dextromethadone (REL-1017) in major depressive disorder (\"MDD\") complete enrollment, as defined in the respective Trial's protocol, with 364 patients per Trial with the last patient in for each trial to be enrolled by December 31, 2022. The remaining 50% of the option shall vest when the Board of Directors or Compensation Committee has determined that 301, 302 and 303 Trials of REL-1017 in MDD report top-line data by December 31, 2023, and meet or exceed their primary and key secondary endpoints as defined in in the respective Trial's protocol."}],"balance_after":300000,"derivative":{"exercise_price":19.03,"expiration_date":"2031-12-17","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001213900-22-029839","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390022029839/ownership.xml","form_type":"4"}},{"id":2254906,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T22:45:02.000Z","date":"2022-05-25","kind":"grant","acquired":true,"shares":651821,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the \"Plan\") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in 16 equal quarterly installments, at 6.25% per quarter, commencing on March 17, 2022."}],"balance_after":1143994,"derivative":{"exercise_price":19.03,"exercise_date":"2022-03-17","expiration_date":"2031-12-17","underlying":"Common Stock","underlying_shares":651821},"source":{"system":"sec-edgar","filing":"0001213900-22-029839","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390022029839/ownership.xml","form_type":"4"}},{"id":2462123,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-12-22T02:31:14.000Z","date":"2021-12-17","kind":"grant","acquired":true,"shares":492173,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 16 equal quarterly installments commencing on March 17, 2022."}],"balance_after":492173,"derivative":{"exercise_price":19.03,"exercise_date":"2022-03-17","expiration_date":"2031-12-17","underlying":"Common Stock","underlying_shares":492173},"source":{"system":"sec-edgar","filing":"0001213900-21-066825","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021066825/ownership.xml","form_type":"4"}},{"id":2794144,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Options to purchase common stock","published_at":"2021-03-11T22:51:28.000Z","date":"2021-03-09","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period."}],"balance_after":99211,"derivative":{"exercise_price":3.24,"exercise_date":"2017-10-20","expiration_date":"2027-10-20","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001213900-21-014918","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021014918/ownership.xml","form_type":"4"}},{"id":2794143,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-03-11T22:51:28.000Z","date":"2021-03-10","kind":"sale","acquired":false,"shares":2983,"price":35.0908,"value":104675.8564,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Sales prices range from $35.00 to $35.37 per share, inclusive."}],"balance_after":88774,"source":{"system":"sec-edgar","filing":"0001213900-21-014918","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021014918/ownership.xml","form_type":"4"}},{"id":2794142,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-03-11T22:51:28.000Z","date":"2021-03-09","kind":"sale","acquired":false,"shares":1800,"price":36.3224,"value":65380.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Sales prices range from $36.02 to $36.65 per share, inclusive."}],"balance_after":91757,"source":{"system":"sec-edgar","filing":"0001213900-21-014918","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021014918/ownership.xml","form_type":"4"}},{"id":2794141,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-03-11T22:51:28.000Z","date":"2021-03-09","kind":"sale","acquired":false,"shares":5217,"price":35.4205,"value":184788.7485,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Sales prices range from $35.00 to $35.94 per share, inclusive."}],"balance_after":93937,"source":{"system":"sec-edgar","filing":"0001213900-21-014918","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021014918/ownership.xml","form_type":"4"}},{"id":2794140,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-03-11T22:51:28.000Z","date":"2021-03-09","kind":"exercise","acquired":true,"shares":10000,"price":3.24,"value":32400.0,"ownership":{"direct":true},"balance_after":98774,"source":{"system":"sec-edgar","filing":"0001213900-21-014918","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021014918/ownership.xml","form_type":"4"}},{"id":2829051,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Options to purchase common stock","published_at":"2021-02-26T21:50:58.000Z","date":"2021-02-24","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period."}],"balance_after":109211,"derivative":{"exercise_price":3.24,"exercise_date":"2017-10-20","expiration_date":"2027-10-20","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001213900-21-012174","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021012174/ownership.xml","form_type":"4"}},{"id":2829050,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-02-26T21:50:58.000Z","date":"2021-02-24","kind":"sale","acquired":false,"shares":303,"price":35.5467,"value":10770.6501,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Sales prices range from $35.45 to $35.65 per share, inclusive."}],"balance_after":88774,"source":{"system":"sec-edgar","filing":"0001213900-21-012174","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021012174/ownership.xml","form_type":"4"}},{"id":2829049,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-02-26T21:50:58.000Z","date":"2021-02-24","kind":"sale","acquired":false,"shares":4860,"price":34.7034,"value":168658.524,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Sales prices range from $34.41 to $35.33 per share, inclusive."}],"balance_after":89077,"source":{"system":"sec-edgar","filing":"0001213900-21-012174","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021012174/ownership.xml","form_type":"4"}},{"id":2829048,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-02-26T21:50:58.000Z","date":"2021-02-24","kind":"sale","acquired":false,"shares":4837,"price":33.6909,"value":162962.8833,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Sales prices range from $33.34 to $34.28 per share, inclusive."}],"balance_after":93937,"source":{"system":"sec-edgar","filing":"0001213900-21-012174","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021012174/ownership.xml","form_type":"4"}},{"id":2829047,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-02-26T21:50:58.000Z","date":"2021-02-24","kind":"exercise","acquired":true,"shares":10000,"price":3.24,"value":32400.0,"ownership":{"direct":true},"balance_after":98774,"source":{"system":"sec-edgar","filing":"0001213900-21-012174","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021012174/ownership.xml","form_type":"4"}},{"id":2858362,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Options to purchase common stock","published_at":"2021-02-16T22:10:17.000Z","date":"2021-02-11","kind":"exercise","acquired":false,"shares":1446,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period."}],"balance_after":119211,"derivative":{"exercise_price":3.24,"exercise_date":"2017-10-20","expiration_date":"2027-10-20","underlying":"Common Stock","underlying_shares":1446},"source":{"system":"sec-edgar","filing":"0001213900-21-009699","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021009699/ownership.xml","form_type":"4"}},{"id":2858361,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-02-16T22:10:17.000Z","date":"2021-02-11","kind":"sale","acquired":false,"shares":1446,"price":35.4346,"value":51238.4316,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Sales prices range from $35.14 to $35.96 per share, inclusive."}],"balance_after":88774,"source":{"system":"sec-edgar","filing":"0001213900-21-009699","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021009699/ownership.xml","form_type":"4"}},{"id":2858360,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-02-16T22:10:17.000Z","date":"2021-02-11","kind":"exercise","acquired":true,"shares":1446,"price":3.24,"value":4685.04,"ownership":{"direct":true},"balance_after":90220,"source":{"system":"sec-edgar","filing":"0001213900-21-009699","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021009699/ownership.xml","form_type":"4"}},{"id":2868590,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Options to purchase common stock","published_at":"2021-02-11T00:25:50.000Z","date":"2021-02-08","kind":"exercise","acquired":false,"shares":11206,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period."}],"balance_after":120657,"derivative":{"exercise_price":3.24,"exercise_date":"2017-10-20","expiration_date":"2027-10-20","underlying":"Common Stock","underlying_shares":11206},"source":{"system":"sec-edgar","filing":"0001213900-21-008204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021008204/ownership.xml","form_type":"4"}},{"id":2868589,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-02-11T00:25:50.000Z","date":"2021-02-10","kind":"sale","acquired":false,"shares":1930,"price":35.2835,"value":68097.155,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Sales prices range from $35.00 to $35.64 per share, inclusive"}],"balance_after":88774,"source":{"system":"sec-edgar","filing":"0001213900-21-008204","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021008204/ownership.xml","form_type":"4"}},{"id":2868588,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-02-11T00:25:50.000Z","date":"2021-02-09","kind":"sale","acquired":false,"shares":5963,"price":35.2069,"value":209938.7447,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Sales prices range from $35.00 to $35.80 per share, inclusive"}],"balance_after":90704,"source":{"system":"sec-edgar","filing":"0001213900-21-008204","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021008204/ownership.xml","form_type":"4"}},{"id":2868587,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-02-11T00:25:50.000Z","date":"2021-02-08","kind":"sale","acquired":false,"shares":3313,"price":35.0283,"value":116048.7579,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Sales prices range from $35.00 to $35.29 per share, inclusive."}],"balance_after":96667,"source":{"system":"sec-edgar","filing":"0001213900-21-008204","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021008204/ownership.xml","form_type":"4"}},{"id":2868586,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-02-11T00:25:50.000Z","date":"2021-02-08","kind":"exercise","acquired":true,"shares":11206,"price":3.24,"value":36307.44,"ownership":{"direct":true},"balance_after":99980,"source":{"system":"sec-edgar","filing":"0001213900-21-008204","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021008204/ownership.xml","form_type":"4"}},{"id":2878806,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Options to purchase common stock","published_at":"2021-02-04T22:42:14.000Z","date":"2021-02-02","kind":"exercise","acquired":false,"shares":13281,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period."}],"balance_after":131863,"derivative":{"exercise_price":3.24,"exercise_date":"2017-10-20","expiration_date":"2027-10-20","underlying":"Common Stock","underlying_shares":13281},"source":{"system":"sec-edgar","filing":"0001213900-21-006837","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021006837/ownership.xml","form_type":"4"}},{"id":2878805,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-02-04T22:42:14.000Z","date":"2021-02-02","kind":"exercise","acquired":true,"shares":13281,"price":3.24,"value":43030.44,"ownership":{"direct":true},"balance_after":88774,"source":{"system":"sec-edgar","filing":"0001213900-21-006837","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021006837/ownership.xml","form_type":"4"}},{"id":2878804,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Options to purchase common stock","published_at":"2021-02-04T22:40:10.000Z","date":"2021-02-02","kind":"exercise","acquired":false,"shares":3278,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period."}],"balance_after":145144,"derivative":{"exercise_price":3.24,"exercise_date":"2017-10-20","expiration_date":"2027-10-20","underlying":"Common Stock","underlying_shares":3278},"source":{"system":"sec-edgar","filing":"0001213900-21-006834","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021006834/ownership.xml","form_type":"4"}},{"id":2878803,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-02-04T22:40:10.000Z","date":"2021-02-03","kind":"sale","acquired":false,"shares":100,"price":35,"value":3500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."}],"balance_after":88874,"source":{"system":"sec-edgar","filing":"0001213900-21-006834","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021006834/ownership.xml","form_type":"4"}},{"id":2878802,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-02-04T22:40:10.000Z","date":"2021-02-02","kind":"sale","acquired":false,"shares":3178,"price":35.0754,"value":111469.6212,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Sales prices range from $35.00 to $35.30 per share, inclusive."}],"balance_after":88874,"source":{"system":"sec-edgar","filing":"0001213900-21-006834","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021006834/ownership.xml","form_type":"4"}},{"id":2878801,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-02-04T22:40:10.000Z","date":"2021-02-02","kind":"exercise","acquired":true,"shares":3278,"price":3.24,"value":10620.72,"ownership":{"direct":true},"balance_after":92052,"source":{"system":"sec-edgar","filing":"0001213900-21-006834","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021006834/ownership.xml","form_type":"4"}},{"id":2889986,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Options to purchase common stock","published_at":"2021-01-29T22:22:28.000Z","date":"2021-01-27","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period."}],"balance_after":148422,"derivative":{"exercise_price":3.24,"exercise_date":"2017-10-20","expiration_date":"2027-10-20","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001213900-21-005448","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021005448/ownership.xml","form_type":"4"}},{"id":2889985,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-01-29T22:22:28.000Z","date":"2021-01-27","kind":"sale","acquired":false,"shares":100,"price":33.43,"value":3343.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020."}],"balance_after":75493,"source":{"system":"sec-edgar","filing":"0001213900-21-005448","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021005448/ownership.xml","form_type":"4"}},{"id":2889984,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-01-29T22:22:28.000Z","date":"2021-01-27","kind":"sale","acquired":false,"shares":5549,"price":32.86,"value":182340.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Sales prices range from $32.42 to $33.41 per share, inclusive."}],"balance_after":75593,"source":{"system":"sec-edgar","filing":"0001213900-21-005448","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021005448/ownership.xml","form_type":"4"}},{"id":2889983,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-01-29T22:22:28.000Z","date":"2021-01-27","kind":"sale","acquired":false,"shares":4351,"price":31.77,"value":138231.27,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Sales prices range from $31.41 to $32.40 per share, inclusive."}],"balance_after":81142,"source":{"system":"sec-edgar","filing":"0001213900-21-005448","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021005448/ownership.xml","form_type":"4"}},{"id":2889982,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-01-29T22:22:28.000Z","date":"2021-01-27","kind":"exercise","acquired":true,"shares":10000,"price":3.24,"value":32400.0,"ownership":{"direct":true},"balance_after":85493,"source":{"system":"sec-edgar","filing":"0001213900-21-005448","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021005448/ownership.xml","form_type":"4"}},{"id":2894837,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Options to purchase common stock","published_at":"2021-01-27T00:29:47.000Z","date":"2021-01-22","kind":"exercise","acquired":false,"shares":4070,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period."}],"balance_after":158422,"derivative":{"exercise_price":3.24,"exercise_date":"2017-10-20","expiration_date":"2027-10-20","underlying":"Common Stock","underlying_shares":4070},"source":{"system":"sec-edgar","filing":"0001213900-21-004480","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021004480/ownership.xml","form_type":"4"}},{"id":2894836,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-01-27T00:29:47.000Z","date":"2021-01-26","kind":"sale","acquired":false,"shares":600,"price":35.15,"value":21090.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Sales prices range from $35.00 to $35.56 per share, inclusive."}],"balance_after":75493,"source":{"system":"sec-edgar","filing":"0001213900-21-004480","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021004480/ownership.xml","form_type":"4"}},{"id":2894835,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-01-27T00:29:47.000Z","date":"2021-01-25","kind":"sale","acquired":false,"shares":1300,"price":35.29,"value":45877.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Sales prices range from $35.01 to $35.51 per share, inclusive."}],"balance_after":76093,"source":{"system":"sec-edgar","filing":"0001213900-21-004480","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021004480/ownership.xml","form_type":"4"}},{"id":2894834,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-01-27T00:29:47.000Z","date":"2021-01-22","kind":"sale","acquired":false,"shares":434,"price":36.15,"value":15689.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Sales prices range from $36.04 to $36.37 per share, inclusive."}],"balance_after":77393,"source":{"system":"sec-edgar","filing":"0001213900-21-004480","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021004480/ownership.xml","form_type":"4"}},{"id":2894833,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-01-27T00:29:47.000Z","date":"2021-01-22","kind":"sale","acquired":false,"shares":1736,"price":35.44,"value":61523.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Sales prices range from $35.04 to $35.98 per share, inclusive."}],"balance_after":77827,"source":{"system":"sec-edgar","filing":"0001213900-21-004480","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021004480/ownership.xml","form_type":"4"}},{"id":2894832,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-01-27T00:29:47.000Z","date":"2021-01-22","kind":"exercise","acquired":true,"shares":4070,"price":3.24,"value":13186.8,"ownership":{"direct":true},"balance_after":79563,"source":{"system":"sec-edgar","filing":"0001213900-21-004480","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021004480/ownership.xml","form_type":"4"}},{"id":2910507,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Options to purchase common stock","published_at":"2021-01-11T21:05:23.000Z","date":"2021-01-07","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest from the date of grant in equal quarterly increments of 6.25% over a four-year period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 25% one year from the date of grant, and thereafter in equal quarterly increments of 6.25% over the following three years. The options are subject to forfeiture upon failure by the Issuer to reach certain corporate objectives in 2021."}],"balance_after":250000,"derivative":{"exercise_price":33.43,"exercise_date":"2022-01-07","expiration_date":"2031-01-07","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001213900-21-001414","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021001414/ownership.xml","form_type":"4"}},{"id":2910506,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Options to purchase common stock","published_at":"2021-01-11T21:05:23.000Z","date":"2021-01-07","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest from the date of grant in equal quarterly increments of 6.25% over a four-year period."}],"balance_after":250000,"derivative":{"exercise_price":33.43,"exercise_date":"2021-04-07","expiration_date":"2031-01-07","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001213900-21-001414","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390021001414/ownership.xml","form_type":"4"}},{"id":3051918,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Options to purchase common stock","published_at":"2020-08-19T20:15:06.000Z","date":"2020-08-18","kind":"exercise","acquired":false,"shares":50008,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period."}],"balance_after":162492,"derivative":{"exercise_price":3.24,"exercise_date":"2017-10-20","expiration_date":"2027-10-20","underlying":"Common Stock","underlying_shares":50008},"source":{"system":"sec-edgar","filing":"0001213900-20-022883","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390020022883/ownership.xml","form_type":"4"}},{"id":3051917,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2020-08-19T20:15:06.000Z","date":"2020-08-18","kind":"tax_withholding","acquired":false,"shares":4151,"price":39.03,"value":162013.53,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects 4,151 shares withheld at the market price of $39.03 per share to fund the cashless exercise of 50,008 options owned by Mr. Traversa, which cashless exercise was approved in advance by the Board of Directors."}],"balance_after":75493,"source":{"system":"sec-edgar","filing":"0001213900-20-022883","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390020022883/ownership.xml","form_type":"4"}},{"id":3051916,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2020-08-19T20:15:06.000Z","date":"2020-08-18","kind":"exercise","acquired":true,"shares":50008,"price":3.24,"value":162025.92,"ownership":{"direct":true},"balance_after":79644,"source":{"system":"sec-edgar","filing":"0001213900-20-022883","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390020022883/ownership.xml","form_type":"4"}},{"id":3332196,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Options to purchase common stock","published_at":"2019-12-23T21:58:30.000Z","date":"2019-12-19","kind":"grant","acquired":true,"shares":350000,"price":43.47,"value":15214500.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant."}],"balance_after":350000,"derivative":{"exercise_price":43.47,"expiration_date":"2029-12-19","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001213900-19-026859","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390019026859/ownership.xml","form_type":"4"}},{"id":3452992,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Options to purchase common stock","published_at":"2019-07-30T21:03:45.000Z","date":"2019-07-29","kind":"grant","acquired":true,"shares":1700000,"price":2.2,"value":3740000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant. In addition, 850,000 options shall be cancelled if Relmada's common stock is not approved for listing on the Nasdaq Stock Market LLC by December 31, 2019."}],"balance_after":1700000,"derivative":{"exercise_price":2.2,"expiration_date":"2029-07-29","underlying":"Common Stock","underlying_shares":1700000},"source":{"system":"sec-edgar","filing":"0001213900-19-014037","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390019014037/ownership.xml","form_type":"4"}},{"id":3723113,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Options to purchase common stock","published_at":"2018-12-20T21:56:10.000Z","date":"2018-12-20","kind":"grant","acquired":true,"shares":900000,"price":1.15,"value":1035000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant."}],"balance_after":900000,"derivative":{"exercise_price":1.15,"expiration_date":"2028-12-20","underlying":"Common Stock","underlying_shares":900000},"source":{"system":"sec-edgar","filing":"0001213900-18-017636","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390018017636/ownership.xml","form_type":"4"}},{"id":4181695,"issuer":{"id":5498,"kind":"organization","name":"RELMADA THERAPEUTICS, INC.","symbol":"RLMD"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Options to purchase common stock","published_at":"2017-10-23T20:42:20.000Z","date":"2017-10-19","kind":"grant","acquired":true,"shares":850000,"price":0.81,"value":688500.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant."}],"balance_after":850000,"derivative":{"exercise_price":0.81,"expiration_date":"2027-10-20","underlying":"Common stock","underlying_shares":850000},"source":{"system":"sec-edgar","filing":"0001213900-17-010837","document":"f4101917traversa_relmada.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390017010837/f4101917traversa_relmada.xml","form_type":"4"}},{"id":4382042,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":71410,"kind":"person","name":"TRAVERSA SERGIO","position":1,"cik":"0001565832","reported_name":"TRAVERSA SERGIO","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options to purchase common stock","published_at":"2017-03-16T20:35:30.000Z","date":"2017-03-14","kind":"grant","acquired":true,"shares":75000,"price":1.39,"value":104250.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant."}],"balance_after":75000,"derivative":{"exercise_price":1.39,"expiration_date":"2027-03-14","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001213900-17-002467","document":"f4031417traversa_actinium.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390017002467/f4031417traversa_actinium.xml","form_type":"4"}}]}